Riley Michael P, Zado Erica, Hutchinson Mathew D, Lin David, Bala Rupa, Garcia Fermin C, Callans David J, Cooper Joshua M, Verdino Ralph J, Dixit Sanjay, Marchlinski Francis E
Hospital of the University of Pennsylvania, Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Philadelphia, Pennsylvania, USA.
J Cardiovasc Electrophysiol. 2014 Jun;25(6):591-6. doi: 10.1111/jce.12387. Epub 2014 Mar 10.
We sought to gain insight into stroke risk after atrial fibrillation (AF) ablation.
We followed 1,990 patients for >1 year (49 ± 29 months) who underwent AF ablation. Prior to stopping oral anticoagulants (OAC), we performed 3-week transtelephonic ECG monitoring (TTM) and taught patients heart rate and pulse assessment. Documented AF or inability to do monitoring or assess pulse precluded stopping OAC in CHADS2 ≥1 patients. OAC was stopped in 546/840 (65%) with CHADS2 = 0; 384/796 (48%) with CHADS2 = 1 and 101/354 (40%) with CHADS2 ≥ 2. Sixteen strokes or TIAs occurred (0.2%/patient-year); 5 in CHADS2 = 0 patients (all off OAC); 5 in CHADS2 = 1 (1 off and 4 on OAC); and 6 in CHADS2 ≥2 (2 off and 4 on OAC). Twelve of 16 patients (75%) with stroke or TIA had documented AF. In patients "off " OAC, stroke rate/year stratified by the CHADS2 score was similar (CHADS2 = 0: 0.28%; CHADS2 = 1: 0.07%; CHADS2 ≥2: 0.50%; P = NS). There was no difference in stroke risk "on" versus "off " OAC in CHADS2 = 1 (0.48% vs. 0.07%) or CHADS2 ≥2 (0.39% vs. 0.50%). Risk of major bleeding per patient year "on" OAC was > "off " OAC (13/1,138 (1.14%) versus 1/832 (0.1%); P<0.016).
Post-AF ablation with OAC guided by TTM and pulse assessment: (1) Overall stroke or TIA rate risk is low and risk is due to recurrent AF and (2) OAC can be stopped in 40% of CHADS2 ≥2 patients with low stroke and hemorrhagic risk.
我们试图深入了解心房颤动(AF)消融术后的中风风险。
我们对1990例接受AF消融术的患者进行了超过1年(49±29个月)的随访。在停用口服抗凝剂(OAC)之前,我们进行了为期3周的电话心电图监测(TTM),并指导患者进行心率和脉搏评估。记录到的AF或无法进行监测或评估脉搏使得CHADS2≥1的患者无法停用OAC。CHADS2 = 0的患者中有546/840(65%)停用了OAC;CHADS2 = 1的患者中有384/796(48%)停用了OAC,CHADS2≥2的患者中有101/354(40%)停用了OAC。发生了16次中风或短暂性脑缺血发作(TIA)(0.2%/患者年);CHADS2 = 0的患者中有5次(均停用OAC);CHADS2 = 1的患者中有5次(1例停用,4例使用OAC);CHADS2≥2的患者中有6次(2例停用,4例使用OAC)。16例发生中风或TIA的患者中有12例(75%)记录到AF。在停用OAC的患者中,按CHADS2评分分层的年中风率相似(CHADS2 = 0:0.28%;CHADS2 = 1:0.07%;CHADS2≥2:0.50%;P = 无显著性差异)。CHADS2 = 1(0.48%对0.07%)或CHADS2≥2(0.39%对0.50%)的患者中,使用OAC与停用OAC的中风风险无差异。使用OAC时每位患者每年的大出血风险高于停用OAC时(13/1138(1.14%)对1/832(0.1%);P<0.016)。
AF消融术后在TTM和脉搏评估的指导下使用OAC:(1)总体中风或TIA风险较低,风险归因于AF复发;(2)对于中风和出血风险较低的CHADS2≥2患者,40%可以停用OAC。